Outcome after resection of one hundred gastrointestinal stromal tumors

Digestive Surgery

Volumn 27, Issue 4, 2010, Pages 313-319

  Krajinovic, K ^a   Germer, C T ^a   Agaimy, A ^b   Wunsch P H ^c   Isbert, C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

Author keywords

Complete tumor resection; Gastrointestinal stromal tumors; Mitotic index; Prognostic factors

Indexed keywords

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; EVALUATION; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; NONPARAMETRIC TEST; PATHOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; COHORT STUDIES; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955117649     PISSN: 02534886     EISSN: 14219883     Source Type: Journal    
DOI: 10.1159/000280022     Document Type: Article

References (37)

1. Nilsson B, Bümming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sablinska K, Kindblom L-G: Gastrointestinal stroma tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - A population based study in western Sweden. Cancer 2005; 103: 821-829.
2. Fletcher CD, Bermann JJ, Corless C, Gorstein F, Lasota J, Longley BJ, O'Leary TJ, Rubin BP, Sobin LH: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
3. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M: Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006; 23: 120-129.
4. De Matteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58.
5. Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H: Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 2003; 90: 332-339.
6. Wu P, Langerman B, Ryan C, Hart J, Swiger S, Posner M: Surgical treatment of gastrointestinal stromal tumours in the imatinib (STI-571) era. Surgery 2003; 134: 656-665.
7. Bucher P, Villinger P, Egger J, Buhler L, Morel P: Management of gastrointestinal stromal tumours: From diagnosis to treatment. Swiss Med Wkly 2004; 134: 145-153.
8. Miettinen M, El-Rifai WE, Sobin LH, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 2002; 33: 478-483.
9. Joensuu H, Fletcher C, Dimitrijevic S, Silbermann S, Roberts P, Demetri G: Management of malignant gastrointestinal stromal tumors. Lancet Oncol 2002; 3: 655-664.
10. Pidhorecky I, Cheney RT, Kraybill WG, et al: Gastrointestinal stromal tumors: Current diagnosis, biologic behavior and management. Ann Surg Oncol 2000; 7: 705-712.
11. Pierie J-PEN, Choudry U, Muzikansky A, et al: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389.
12. Miettinen M, Makhlouf H, Sobin L, Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with longterm follow up. Am J Surg Pathol 2006; 30: 477-489.
13. Gupta M, Sheppard BC, Corless CL, Mac-Donell KR, Blanke CD, Billingsley KG: Outcome following surgical therapy for gastrointestinal stromal tumors. J Gastrointest Surg 2006; 10: 1099-1105.
14. Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumours (GISTs): A review. Eur J Cancer 2002; 38(suppl 5):S39-S51.
15. Greenson JK: Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003; 16: 366-375.
16. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF: Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000; 88: 66-74.
17. Tsukuda K, Hirat R, Miyake T, et al: The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute. Surg Today 2007; 37: 953-957.
18. Samiian L, Mitchell W, Velanovich V: Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg 2004; 70: 187-192.
19. Hsu KH, Yang TM, Shan YS, Lin PW: Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am J Surg 2007; 194: 148-152.
20. Mucciarini C, Rossi G, Bertolini F, Valli R, et al: Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007; 7: 230.
21. Chandrajit PR, Stanley WA: How I Do It: Surgical Management of Gastrointestinal Stromal Tumors. J Gastrointest Surg 2008; 12: 1592-1599.
22. DeMatteo RP: A phase III randomized double-blind study of adjuvant STI571(Gleevec) versus placebo in patients following the resection of primary gastrointestinal stromal tumor (GIST), 2001.
23. DeMatteo RP: A phase II study of adjuvant STI571 (Gleevec) therapy in patients following completely resected high-risk primary gastrointestonal stromal tumor (GIST), 2001.
24. Casali PG: Phase III randomized study of adjuvant imatinib mesylate versus observation only in patients with completely resected localizes gastrointestinal stromal tumor at intermediate-or high-risk of relapse, 2004.
25. Joensuu H: Phase III randomized study of short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk for recurrence, 2004.
26. Miettinen M, Salomo-Rikala M, Sobin LH, Lasota J: Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunhistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000; 24: 1339-1352.
27. Blay JY, Bonvalot S, Casali P, et al: Consensus meeting for the management of gastrointestinal stromal tumors: Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.
28. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hagendoorn PCW, van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134.
29. Gold JS, DeMatteo RP: Combined surgical and molecular therapy: The gastrointestinal stromal tumor model. Ann Surg 2006; 244: 176-184.
30. Wakai T, Kanda T, Hirota S, et al: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumor is associated with a second KIT mutation. Br J Cancer 2004; 90: 2059-2061.
31. Tamborini E, Bonadiman L, Greco A, et al: A new mutation in the KIT ATP pocket causses acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127: 294-299.
32. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher C, Sandau K, McDougall K, Ou W, Chen C, Fletcher JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774.
33. Gold JS, DeMatteo RP: Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): Racing against resistance. Ann Surg Oncol 2007; 14: 1247-1248.
34. Andtbacka RHI, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PWT, Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Raymond K, Feig BW: Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
35. Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, LeCesne A, Bonvalot S: Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004; 30: 1098-1103.
36. Hohenberger P, Reichardt P, Gebauer B, Wardelmann E: Gastrointestinale Stro matumoren - derzeitige Konzepte der chirurgischen Therapie. Dtsch Med Wochenschr 2004; 129: 1817-1820.
37. Bauer S, Hartmann JT, de Wit M, et al: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005; 117: 316-332.